The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Weight loss drugs are being hailed as revolutionary tools in the fight against obesity. Originally developed for diabetes, these drugs have gone mainstream - recommended by doctors, and sought after ...

The evolution of controversial new weight loss drugs is shining a spotlight on a crippling, little-understood food phenomenon ...